Lets COMPARE this 3rd Quarter and 2016 3rd Quarter - SHALL WE:
MAY 2016 OS - 122.5 Million Shares CASH ON HAND - 5.3 Million CASH Available via ASPIRE - 25 Million SHELF REG - 45 Million
OVERVIEW OF PIPELINE: K - Still in Phase 1 at DF and BIDMC P - Enrollment complete in phase 2a waiting on data at the time the Q came out B - Submitted SPA for Absssi phase 3 - Received comments back from FDA - CTIX discussing next steps B-OM - Phase 2 underway and they replaced the CRO during this period due to lack of progress
MAY 2017 OS - 131.3 Million Shares CASH ON HAND - 5.6 Million CASH Available via ASPIRE - 16 Million Shelf Reg - 45 Million
OVERVIEW OF PIPELINE: K - Completed Phase 1 and provided data; Initiated a phase 2 trial for OC k- ORAL Formulation underway --- Bridging tox studies started in Jan 2017 P - Data for phase 2a was successful; Initiated a phase 2b trial with dosing much higher B Absssi - Decided to hold tight on B phase 3 for Absssi while share price was so low to limit dilution for a 30 million trial B-OM - Released interim data that was phenomenal but the data was only for about 20 patients. Recruitment still underway B-UP - Initiated a phase 2 PoC trial - this is in the final cohort and data looks superb to date!
____________________________________________________ So - yes the OS went up about 9 Million since last year same time. But CTIX was able to start 3 NEW mid stage trials and begin bridge tox studies for K Oral with that money. I'd say GREAT JOB CTIX!!!!